The size of the North America Atrial Fibrillation Surgery Market is valued at USD 0.57 Billion in 2022. This value is expected to grow at a CAGR of 12.5% to reach USD 1.03 million by 2027.
Y-O-Y growth in the incidence of obesity is accelerating the atrial fibrillation market in this region during the forecast period. The high intake of alcohol among North American countries such as the United States and Canada is estimated to favor market growth. For instance, nearly 164.8 million people aged 12 years and above in the U.S. are addicted to tobacco, alcohol, or illicit drugs, according to the National Survey on Drug Use and Health in 2018. Advanced infrastructure in healthcare and eminent endorsement of high-grade advanced technologies are propelling the market growth. Moreover, obtaining devices from other key players and novel innovation in the market plays a vital role in the quickly growing atrial fibrillation market, assisting the vendors in enlarging the portfolios.
The pricing pressure of the devices associated with atrial fibrillation and its procedure for the treatment are factors impeding the market growth in the region. The shortage of imperative infrastructure to control smooth atrial fibrillation processes among a few emerging areas may restrain the market growth over the estimated period.
This research report on the North America Atrial Fibrillation Surgery Market has been segmented and sub-segmented into the following categories:
Based on the region, the U.S. leads the Atrial Fibrillation Surgery market due to the availability of highly advanced healthcare infrastructure and the adoption of highly advanced technologies.
North America is governing the market in atrial fibrillation surgery because of the rising number of patient populations suffering from heart-related diseases and a surge in awareness of cardiovascular illnesses. The U.S. is anticipated to dominate the market in North America as an escalating geriatric population, and a growing number of healthcare innovations are fueling the market. The region's key players focus on the approval and launch of new devices in enlarging their products. For instance, CardioFocus, Inc. has received the US FDA acceptance for its next-generation HeartLight X3 Endoscopic Ablation System to treat drug-refractory periodic symptomatic paroxysmal atrial fibrillation.
The U.S. is the key for novel technology adapter and the most enhanced region in serving the state-of-the-art services devices in atrial fibrillation procedures. Canada is the next dominating country in the atrial fibrillation market of the area. Canada's market is growing substantially with the approvable reimbursement policies and latest technologies and utilization of innovative techniques.
Promising Companies dominating the North America Atrial Fibrillation Surgery Market profiled in the Report are Biosense Webster, Inc., Boston Scientific Corporation, St. Jude Medical, Inc., Articure, Inc., Medtronic, Inc., Cardima, Inc. Cardiofocus, Inc., nContact, Inc., and Biotronik SE & Co.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com